Cinnaxole Pharma

Company Overview

Snapshot

Founded in December 2014 by Zvika Weiss and Tomer Cohen, Cinnaxole Pharma operates with 1–10 employees. The company is currently in the Pre-Funding stage.

Business overview

Cinnaxole Pharma is focused on developing antiviral vaccines for poultry, specifically targeting envelope virus diseases. The company's core technology involves a cinnamon-based antiviral extract, with its initial product designed for in-ovo vaccination against Newcastle disease, a severe infection affecting domestic poultry. Cinnaxole Pharma aims to provide more efficient and cost-effective vaccination solutions compared to traditional methods, serving the animal health and agriculture markets within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is Cinnaxole Pharma's primary focus?

Cinnaxole Pharma is developing antiviral vaccines for poultry, with an initial focus on creating a cinnamon-based extract for in-ovo vaccination against Newcastle disease.

When was Cinnaxole Pharma founded?

Cinnaxole Pharma was founded in December 2014.

Who are the co-founders of Cinnaxole Pharma?

Zvika Weiss and Tomer Cohen are the co-founders of Cinnaxole Pharma.

What market does Cinnaxole Pharma primarily serve?

Cinnaxole Pharma primarily serves the animal health market, specifically focusing on poultry.

What is the current stage of Cinnaxole Pharma's product development?

Cinnaxole Pharma's product is currently in the R&D stage, focusing on developing a cinnamon-based antiviral extract for vaccinations against envelope virus diseases.